{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:37:25Z","timestamp":1793047045143,"version":"4.5.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17239"],"award-info":[{"award-number":["20K17239"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K11605"],"award-info":[{"award-number":["24K11605"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["22ek0410097"],"award-info":[{"award-number":["22ek0410097"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25ek0410138"],"award-info":[{"award-number":["25ek0410138"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015542","name":"GlaxoSmithKline Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008664","name":"Ono Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40291-026-00877-y","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T10:20:17Z","timestamp":1787394017000},"page":"909-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrative Omics of Eosinophils in Asthma and COPD: Deciphering Molecular Signatures for Targeted Therapy"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3189-1702","authenticated-orcid":false,"given":"Jun","family":"Miyata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1694-8432","authenticated-orcid":false,"given":"Keeya","family":"Sunata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-2451","authenticated-orcid":false,"given":"Hisashi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5046-3762","authenticated-orcid":false,"given":"Shotaro","family":"Chubachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-6611","authenticated-orcid":false,"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-8199","authenticated-orcid":false,"given":"Yusuke","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9902-0463","authenticated-orcid":false,"given":"Makoto","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7460-1990","authenticated-orcid":false,"given":"Koichi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"10","key":"877_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2213-2600(25)00174-2","volume":"13","author":"M Lommatzsch","year":"2025","unstructured":"Lommatzsch M, Buhl R, Bergmann KC, Brusselle GG, Canonica GW, Jackson DJ, et al. Eosinophils in asthma phenotypes: perpetrators or guilty by association? Lancet Respir Med. 2025;13(10):943\u201350.","journal-title":"Lancet Respir Med"},{"key":"877_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/17534666251335800","volume":"19","author":"M Vanetti","year":"2025","unstructured":"Vanetti M, Visca D, Ardesi F, Zappa M, Pignatti P, Spanevello A. Eosinophils in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2025;19:17534666251335800.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"877_CR3","first-page":"39","volume":"1","author":"S Saha","year":"2006","unstructured":"Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39\u201347.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"877_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MCP.0000000000000660","volume":"26","author":"CF McDonald","year":"2020","unstructured":"McDonald CF. Eosinophils in chronic obstructive pulmonary disease: are they just another biomarker? Curr Opin Pulm Med. 2020;26(2):169\u201374.","journal-title":"Curr Opin Pulm Med"},{"issue":"9347","key":"877_CR5","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","volume":"360","author":"RH Green","year":"2002","unstructured":"Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715\u201321.","journal-title":"Lancet"},{"issue":"1","key":"877_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.aller.2009.10.006","volume":"38","author":"L Garcia-Marcos","year":"2010","unstructured":"Garcia-Marcos L, Brand PL. The utility of sputum eosinophils and exhaled nitric oxide for monitoring asthma control with special attention to childhood asthma. Allergol Immunopathol (Madr). 2010;38(1):41\u20136.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"4","key":"877_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaci.2013.06.007","volume":"132","author":"A Malinovschi","year":"2013","unstructured":"Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol. 2013;132(4):821-7.e1-5.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"877_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849\u201358.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"877_CR9","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/cea.13137","volume":"48","author":"I Mogensen","year":"2018","unstructured":"Mogensen I, Alving K, Jacinto T, Fonseca J, Janson C, Malinovschi A. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007\u201312. Clin Exp Allergy. 2018;48(8):935\u201343.","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"877_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201143","volume":"13","author":"M Kerkhof","year":"2018","unstructured":"Kerkhof M, Tran TN, van den Berge M, Brusselle GG, Gopalan G, Jones RCM, et al. Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS ONE. 2018;13(7):e0201143.","journal-title":"PLoS ONE"},{"issue":"16","key":"877_CR11","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.2174\/1389450119666180212120012","volume":"19","author":"K Kostikas","year":"2018","unstructured":"Kostikas K, Brindicci C, Patalano F. Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD. Curr Drug Targets. 2018;19(16):1882\u201396.","journal-title":"Curr Drug Targets"},{"issue":"3","key":"877_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100110","volume":"13","author":"H Backman","year":"2020","unstructured":"Backman H, Lindberg A, Hedman L, Stridsman C, Jansson SA, Sandstr\u00f6m T, et al. FEV(1) decline in relation to blood eosinophils and neutrophils in a population-based asthma cohort. World Allergy Organ J. 2020;13(3):100110.","journal-title":"World Allergy Organ J"},{"issue":"3","key":"877_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/pai.13403","volume":"32","author":"N Mallah","year":"2021","unstructured":"Mallah N, Rodriguez-Segade S, Gonzalez-Barcala FJ, Takkouche B. Blood eosinophil count as predictor of asthma exacerbation. A meta-analysis. Pediatr Allergy Immunol. 2021;32(3):465\u201378.","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"877_CR14","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jaip.2022.02.020","volume":"10","author":"M Abdo","year":"2022","unstructured":"Abdo M, Pedersen F, Kirsten AM, Veith V, Biller H, Trinkmann F, et al. Longitudinal impact of sputum inflammatory phenotypes on small airway dysfunction and disease outcomes in asthma. J Allergy Clin Immunol Pract. 2022;10(6):1545-53.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"877_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48381-1","volume":"13","author":"VA Barcellos","year":"2023","unstructured":"Barcellos VA, Dos Santos VCH, Moreira M\u00c2F, Dalcin PTR. Asthma control and sputum eosinophils in adult patients: a cross-sectional study in southern Brazil. Sci Rep. 2023;13(1):21464.","journal-title":"Sci Rep"},{"issue":"1","key":"877_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2169\/internalmedicine.9339-22","volume":"62","author":"T Hirano","year":"2023","unstructured":"Hirano T, Matsunaga K. Measurement of blood eosinophils in asthma and chronic obstructive pulmonary disease. Intern Med. 2023;62(1):21\u20135.","journal-title":"Intern Med"},{"issue":"10","key":"877_CR17","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1111\/all.16242","volume":"79","author":"H Rupani","year":"2024","unstructured":"Rupani H, Busse WW, Howarth PH, Bardin PG, Adcock IM, Konno S, et al. Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma. Allergy. 2024;79(10):2589\u2013604.","journal-title":"Allergy"},{"key":"877_CR18","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2147\/COPD.S100338","volume":"11","author":"NA Negewo","year":"2016","unstructured":"Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1495\u2013504.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9","key":"877_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","volume":"193","author":"S Vedel-Krogh","year":"2016","unstructured":"Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"877_CR20","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","volume":"5","author":"AT Hastie","year":"2017","unstructured":"Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956\u201367.","journal-title":"Lancet Respir Med"},{"key":"877_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rmed.2018.03.016","volume":"138","author":"G Brusselle","year":"2018","unstructured":"Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med. 2018;138:21\u201331.","journal-title":"Respir Med"},{"issue":"6","key":"877_CR22","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","volume":"141","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037-47.e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"877_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1130-y","volume":"20","author":"CF Vogelmeier","year":"2019","unstructured":"Vogelmeier CF, Kostikas K, Fang J, Tian H, Jones B, Morgan CL, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178.","journal-title":"Respir Res"},{"issue":"3","key":"877_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4046\/trd.2020.0026","volume":"83","author":"D Singh","year":"2020","unstructured":"Singh D. Blood eosinophil counts in chronic obstructive pulmonary disease: a biomarker of inhaled corticosteroid effects. Tuberc Respir Dis (Seoul). 2020;83(3):185\u201394.","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"877_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030404","author":"K Nishimura","year":"2021","unstructured":"Nishimura K, Kusunose M, Sanda R, Mori M, Shibayama A, Nakayasu K. Is blood eosinophil count a biomarker for chronic obstructive pulmonary disease in a real-world clinical setting? Predictive property and longitudinal stability in Japanese patients. Diagnostics (Basel). 2021. https:\/\/doi.org\/10.3390\/diagnostics11030404.","journal-title":"Diagnostics (Basel)"},{"key":"877_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2147\/COPD.S265275","volume":"16","author":"R Prudente","year":"2021","unstructured":"Prudente R, Ferrari R, Mesquita CB, Machado LHS, Franco EAT, Godoy I, et al. Peripheral blood eosinophils and nine years mortality in COPD patients. Int J Chron Obstruct Pulmon Dis. 2021;16:979\u201385.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"877_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00838-2020","author":"WC Tan","year":"2021","unstructured":"Tan WC, Bourbeau J, Nadeau G, Wang W, Barnes N, Landis SH, et al. High eosinophil counts predict decline in FEV(1): results from the CanCOLD study. Eur Respir J. 2021. https:\/\/doi.org\/10.1183\/13993003.00838-2020.","journal-title":"Eur Respir J"},{"issue":"3","key":"877_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.alit.2022.11.012","volume":"72","author":"Y Abe","year":"2023","unstructured":"Abe Y, Suzuki M, Kimura H, Shimizu K, Takei N, Oguma A, et al. Blood eosinophil count variability in chronic obstructive pulmonary disease and severe asthma. Allergol Int. 2023;72(3):402\u201310.","journal-title":"Allergol Int"},{"key":"877_CR29","first-page":"283","volume":"7","author":"Y Kitaguchi","year":"2012","unstructured":"Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"877_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4168\/aair.2014.6.4.316","volume":"6","author":"JJ Fu","year":"2014","unstructured":"Fu JJ, McDonald VM, Gibson PG, Simpson JL. Systemic inflammation in older adults with asthma-COPD overlap syndrome. Allergy Asthma Immunol Res. 2014;6(4):316\u201324.","journal-title":"Allergy Asthma Immunol Res"},{"key":"877_CR31","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.2147\/COPD.S142466","volume":"12","author":"J Gao","year":"2017","unstructured":"Gao J, Zhou W, Chen B, Lin W, Wu S, Wu F. Sputum cell count: biomarkers in the differentiation of asthma, COPD and asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis. 2017;12:2703\u201310.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"877_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1080\/15412555.2020.1761314","volume":"17","author":"G Gava","year":"2020","unstructured":"Gava G, N\u00fa\u00f1ez A, Esquinas C, Sarasate M, Loeb E, Pirina P, et al. Analysis of blood biomarkers in patients with chronic obstructive pulmonary disease (COPD) and with asthma-COPD overlap (ACO). COPD. 2020;17(3):306\u201310.","journal-title":"COPD"},{"issue":"1","key":"877_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/resp.13841","volume":"26","author":"SA Hiles","year":"2021","unstructured":"Hiles SA, Gibson PG, McDonald VM. Disease burden of eosinophilic airway disease: comparing severe asthma, COPD and asthma-COPD overlap. Respirology. 2021;26(1):52\u201361.","journal-title":"Respirology"},{"issue":"2","key":"877_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.alit.2020.09.004","volume":"70","author":"T Mochimaru","year":"2021","unstructured":"Mochimaru T, Chubachi S, Irie H, Sakurai K, Okuzumi S, Sunata K, et al. Blood eosinophil and neutrophil counts differentially identify frequent exacerbation in patients with COPD with physician-diagnosed asthma and COPD. Allergol Int. 2021;70(2):255\u20137.","journal-title":"Allergol Int"},{"key":"877_CR35","doi-asserted-by":"publisher","first-page":"1045503","DOI":"10.3389\/fmed.2022.1045503","volume":"9","author":"H Ma","year":"2022","unstructured":"Ma H, Yang L, Liu L, Zhou Y, Guo X, Wu S, et al. Using inflammatory index to distinguish asthma, asthma-COPD overlap and COPD: a retrospective observational study. Front Med (Lausanne). 2022;9:1045503.","journal-title":"Front Med (Lausanne)."},{"issue":"9842","key":"877_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"},{"issue":"13","key":"877_CR37","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"5","key":"877_CR38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390\u2013400.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"877_CR39","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"877_CR40","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115\u201327.","journal-title":"Lancet"},{"issue":"17","key":"877_CR41","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","volume":"377","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613\u201329.","journal-title":"N Engl J Med"},{"issue":"11","key":"877_CR42","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","volume":"381","author":"GJ Criner","year":"2019","unstructured":"Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med. 2019;381(11):1023\u201334.","journal-title":"N Engl J Med"},{"key":"877_CR43","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2147\/COPD.S294333","volume":"16","author":"ID Pavord","year":"2021","unstructured":"Pavord ID, Chapman KR, Bafadhel M, Sciurba FC, Bradford ES, Schweiker Harris S, et al. Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755\u201370.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"877_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205\u201314.","journal-title":"N Engl J Med"},{"issue":"24","key":"877_CR45","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med. 2024;390(24):2274\u201383.","journal-title":"N Engl J Med"},{"issue":"1","key":"877_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","volume":"13","author":"D Singh","year":"2025","unstructured":"Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, et al. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial. Lancet Respir Med. 2025;13(1):47\u201358.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"877_CR47","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/nri.2017.95","volume":"17","author":"PF Weller","year":"2017","unstructured":"Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017;17(12):746\u201360.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"877_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.alit.2020.09.002","volume":"70","author":"A Aoki","year":"2021","unstructured":"Aoki A, Hirahara K, Kiuchi M, Nakayama T. Eosinophils: cells known for over 140 years with broad and new functions. Allergol Int. 2021;70(1):3\u20138.","journal-title":"Allergol Int"},{"key":"877_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137075","author":"JM Rodrigo-Mu\u00f1oz","year":"2021","unstructured":"Rodrigo-Mu\u00f1oz JM, Gil-Mart\u00ednez M, Sastre B, Del Pozo V. Emerging evidence for pleiotropism of eosinophils. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22137075.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"877_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141740","volume":"10","author":"C Barnig","year":"2015","unstructured":"Barnig C, Alsaleh G, Jung N, Demb\u00e9l\u00e9 D, Paul N, Poirot A, et al. Circulating human eosinophils share a similar transcriptional profile in asthma and other hypereosinophilic disorders. PLoS ONE. 2015;10(11):e0141740.","journal-title":"PLoS ONE"},{"issue":"1","key":"877_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2015.06.012","volume":"167","author":"ZJ Shen","year":"2015","unstructured":"Shen ZJ, Hu J, Esnault S, Dozmorov I, Malter JS. RNA Seq profiling reveals a novel expression pattern of TGF-\u03b2 target genes in human blood eosinophils. Immunol Lett. 2015;167(1):1\u201310.","journal-title":"Immunol Lett"},{"issue":"2","key":"877_CR52","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4049\/jimmunol.1801668","volume":"203","author":"RK Nelson","year":"2019","unstructured":"Nelson RK, Brickner H, Panwar B, Ram\u00edrez-Su\u00e1stegui C, Herrera-de la Mata S, Liu N, et al. Human eosinophils express a distinct gene expression program in response to IL-3 compared with common \u03b2-chain cytokines il-5 and gm-csf. J Immunol. 2019;203(2):329\u201337.","journal-title":"J Immunol"},{"issue":"4","key":"877_CR53","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaci.2024.05.029","volume":"154","author":"N Ben-Baruch Morgenstern","year":"2024","unstructured":"Ben-Baruch Morgenstern N, Rochman M, Kotliar M, Dunn JLM, Mack L, Besse J, et al. Single-cell RNA-sequencing of human eosinophils in allergic inflammation in the esophagus. J Allergy Clin Immunol. 2024;154(4):974\u201387.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"877_CR54","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jaci.2024.05.014","volume":"154","author":"N Iwasaki","year":"2024","unstructured":"Iwasaki N, Poposki JA, Oka A, Kidoguchi M, Klingler AI, Suh LA, et al. Single cell RNA sequencing of human eosinophils from nasal polyps reveals eosinophil heterogeneity in chronic rhinosinusitis tissue. J Allergy Clin Immunol. 2024;154(4):952\u201364.","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"877_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70110","volume":"28","author":"K Mycroft","year":"2024","unstructured":"Mycroft K, Proboszcz M, Papli\u0144ska-Goryca M, Krenke R, G\u00f3rska K. Transcriptional profiles of peripheral eosinophils in chronic obstructive pulmonary disease and asthma\u2014an exploratory study. J Cell Mol Med. 2024;28(20):e70110.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"877_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112609","volume":"28","author":"K Goss","year":"2025","unstructured":"Goss K, Grant ML, Caldwell C, Dallalio GA, Stephenson ST, Fitzpatrick AM, et al. Single-cell RNA-sequencing of circulating eosinophils from asthma patients reveals an inflammatory signature. iScience. 2025;28(6):112609.","journal-title":"iScience"},{"issue":"2","key":"877_CR57","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/all.16213","volume":"80","author":"JM Rodrigo-Mu\u00f1oz","year":"2025","unstructured":"Rodrigo-Mu\u00f1oz JM, Naharro-Gonz\u00e1lez S, Callejas S, Rela\u00f1o-Ruperez C, Torroja C, Benguria A, et al. Single-cell RNA sequencing of human blood eosinophils reveals plasticity and absence of canonical cell subsets. Allergy. 2025;80(2):570\u20134.","journal-title":"Allergy"},{"issue":"7","key":"877_CR58","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/pmic.200401086","volume":"5","author":"SW Yoon","year":"2005","unstructured":"Yoon SW, Kim TY, Sung MH, Kim CJ, Poo H. Comparative proteomic analysis of peripheral blood eosinophils from healthy donors and atopic dermatitis patients with eosinophilia. Proteomics. 2005;5(7):1987\u201395.","journal-title":"Proteomics"},{"issue":"10","key":"877_CR59","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/prca.200900043","volume":"3","author":"C Straub","year":"2009","unstructured":"Straub C, Pazdrak K, Young TW, Stafford SJ, Wu Z, Wiktorowicz JE, et al. Toward the proteome of the human peripheral blood eosinophil. Proteomics Clin Appl. 2009;3(10):1151\u201373.","journal-title":"Proteomics Clin Appl"},{"issue":"6","key":"877_CR60","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1021\/pr800984e","volume":"8","author":"C Woschnagg","year":"2009","unstructured":"Woschnagg C, Forsberg J, Engstr\u00f6m A, Odreman F, Venge P, Garcia RC. The human eosinophil proteome. Changes induced by birch pollen allergy. J Proteome Res. 2009;8(6):2720\u201332.","journal-title":"J Proteome Res"},{"issue":"5","key":"877_CR61","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1021\/acs.jproteome.6b00006","volume":"15","author":"EM Wilkerson","year":"2016","unstructured":"Wilkerson EM, Johansson MW, Hebert AS, Westphall MS, Mathur SK, Jarjour NN, et al. The peripheral blood eosinophil proteome. J Proteome Res. 2016;15(5):1524\u201333.","journal-title":"J Proteome Res"},{"issue":"8","key":"877_CR62","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1021\/acs.jproteome.6b00367","volume":"16","author":"KV Soman","year":"2017","unstructured":"Soman KV, Stafford SJ, Pazdrak K, Wu Z, Luo X, White WI, et al. Activation of human peripheral blood eosinophils by cytokines in a comparative time-course proteomic\/phosphoproteomic study. J Proteome Res. 2017;16(8):2663\u201379.","journal-title":"J Proteome Res"},{"issue":"2","key":"877_CR63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaci.2012.07.048","volume":"131","author":"J Miyata","year":"2013","unstructured":"Miyata J, Fukunaga K, Iwamoto R, Isobe Y, Niimi K, Takamiya R, et al. Dysregulated synthesis of protectin D1 in eosinophils from patients with severe asthma. J Allergy Clin Immunol. 2013;131(2):353-60.e1-2.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"877_CR64","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/all.13726","volume":"74","author":"J Miyata","year":"2019","unstructured":"Miyata J, Fukunaga K, Kawashima Y, Watanabe T, Saitoh A, Hirosaki T, et al. Dysregulated fatty acid metabolism in nasal polyp-derived eosinophils from patients with chronic rhinosinusitis. Allergy. 2019;74(6):1113\u201324.","journal-title":"Allergy"},{"issue":"11","key":"877_CR65","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1111\/all.16215","volume":"79","author":"H Sasaki","year":"2024","unstructured":"Sasaki H, Miyata J, Kawashima Y, Konno R, Ishikawa M, Hasegawa Y, et al. Distinct roles of types 1 and 2 interferons in human eosinophil regulation: a multi-omics analysis. Allergy. 2024;79(11):3141\u20135.","journal-title":"Allergy"},{"key":"877_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1445769","volume":"15","author":"K Sunata","year":"2024","unstructured":"Sunata K, Miyata J, Kawashima Y, Konno R, Ishikawa M, Hasegawa Y, et al. Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study. Front Immunol. 2024;15:1445769.","journal-title":"Front Immunol"},{"issue":"5","key":"877_CR67","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jaci.2024.07.012","volume":"154","author":"K Sunata","year":"2024","unstructured":"Sunata K, Miyata J, Kawashima Y, Konno R, Ishikawa M, Hasegawa Y, et al. Multiomics analysis identified IL-4-induced IL1RL1(high) eosinophils characterized by prominent cysteinyl leukotriene metabolism. J Allergy Clin Immunol. 2024;154(5):1277\u201388.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"877_CR68","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jaci.2025.10.029","volume":"157","author":"J Miyata","year":"2026","unstructured":"Miyata J, Sunata K, Sasaki H, Kawashima Y, Otsu Y, Onozato R, et al. Multiomics insights into retinoic acid-mediated regulation of eosinophils in severe asthma. J Allergy Clin Immunol. 2026;157(2):531\u20139.","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"877_CR69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.alit.2024.08.009","volume":"74","author":"H Sasaki","year":"2025","unstructured":"Sasaki H, Miyata J, Kawashima Y, Konno R, Ishikawa M, Hasegawa Y, et al. Aspergillus fumigatus extract modulates human eosinophils via NOD2 and oxidative stress. Allergol Int. 2025;74(1):156\u201365.","journal-title":"Allergol Int"},{"issue":"4","key":"877_CR70","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","volume":"50","author":"BN Lambrecht","year":"2019","unstructured":"Lambrecht BN, Hammad H, Fahy JV. The cytokines of asthma. Immunity. 2019;50(4):975\u201391.","journal-title":"Immunity"},{"issue":"6","key":"877_CR71","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","volume":"184","author":"H Hammad","year":"2021","unstructured":"Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184(6):1469\u201385.","journal-title":"Cell"},{"key":"877_CR72","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00150-2024","author":"F Polverino","year":"2024","unstructured":"Polverino F, Sin DD. Type 2 airway inflammation in COPD. Eur Respir J. 2024. https:\/\/doi.org\/10.1183\/13993003.00150-2024.","journal-title":"Eur Respir J"},{"issue":"8","key":"877_CR73","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41590-025-02212-9","volume":"26","author":"BN Lambrecht","year":"2025","unstructured":"Lambrecht BN, Ahmed E, Hammad H. The immunology of asthma. Nat Immunol. 2025;26(8):1233\u201345.","journal-title":"Nat Immunol"},{"issue":"2","key":"877_CR74","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/08820139.2025.2583274","volume":"55","author":"S Gao","year":"2026","unstructured":"Gao S, Liu X. Type 2 inflammatory phenotypes in chronic obstructive pulmonary disease and asthma: similarities and differences. Immunol Invest. 2026;55(2):309\u201332.","journal-title":"Immunol Invest"},{"issue":"3","key":"877_CR75","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jaci.2015.05.039","volume":"136","author":"H Ortega","year":"2015","unstructured":"Ortega H, Katz L, Gunsoy N, Keene O, Yancey S. Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2015;136(3):825\u20136.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"877_CR76","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","volume":"3","author":"S Pascoe","year":"2015","unstructured":"Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435\u201342.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"877_CR77","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","volume":"47","author":"NC Barnes","year":"2016","unstructured":"Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374\u201382.","journal-title":"Eur Respir J"},{"issue":"2","key":"877_CR78","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","volume":"71","author":"ID Pavord","year":"2016","unstructured":"Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD. Thorax. 2016;71(2):118\u201325.","journal-title":"Thorax"},{"issue":"5","key":"877_CR79","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","volume":"4","author":"H Watz","year":"2016","unstructured":"Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390\u20138.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"877_CR80","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","volume":"7","author":"S Pascoe","year":"2019","unstructured":"Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745\u201356.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"877_CR81","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40265-026-02303-3","volume":"86","author":"M Cazzola","year":"2026","unstructured":"Cazzola M, Bajpai J, Calzetta L, Matera MG, Rogliani P. GOLD 2026: transforming COPD management with early intervention, multi-dimensional assessment, and personalized care. Drugs. 2026;86(5):581\u201397.","journal-title":"Drugs"},{"issue":"17","key":"877_CR82","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","volume":"392","author":"FC Sciurba","year":"2025","unstructured":"Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. N Engl J Med. 2025;392(17):1710\u201320.","journal-title":"N Engl J Med"},{"key":"877_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2013.00027","volume":"4","author":"T Luna-Gomes","year":"2013","unstructured":"Luna-Gomes T, Bozza PT, Bandeira-Melo C. Eosinophil recruitment and activation: the role of lipid mediators. Front Pharmacol. 2013;4:27.","journal-title":"Front Pharmacol"},{"issue":"1","key":"877_CR84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri3341","volume":"13","author":"HF Rosenberg","year":"2013","unstructured":"Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9\u201322.","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"877_CR85","doi-asserted-by":"publisher","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","volume":"289","author":"KR Acharya","year":"2014","unstructured":"Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014;289(25):17406\u201315.","journal-title":"J Biol Chem"},{"issue":"1","key":"877_CR86","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.alit.2019.06.002","volume":"69","author":"J Miyata","year":"2020","unstructured":"Miyata J, Fukunaga K, Kawashima Y, Ohara O, Arita M. Cysteinyl leukotriene metabolism of human eosinophils in allergic disease. Allergol Int. 2020;69(1):28\u201334.","journal-title":"Allergol Int"},{"key":"877_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2020.106477","volume":"150","author":"J Miyata","year":"2020","unstructured":"Miyata J, Fukunaga K, Kawashima Y, Ohara O, Kawana A, Asano K, et al. Dysregulated metabolism of polyunsaturated fatty acids in eosinophilic allergic diseases. Prostaglandins Other Lipid Mediat. 2020;150:106477.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"8","key":"877_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-016-0634-5","volume":"16","author":"S Ueki","year":"2016","unstructured":"Ueki S, Tokunaga T, Fujieda S, Honda K, Hirokawa M, Spencer LA, et al. Eosinophil ETosis and DNA traps: a new look at eosinophilic inflammation. Curr Allergy Asthma Rep. 2016;16(8):54.","journal-title":"Curr Allergy Asthma Rep"},{"key":"877_CR89","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3389\/fimmu.2018.02763","volume":"9","author":"M Mukherjee","year":"2018","unstructured":"Mukherjee M, Lacy P, Ueki S. Eosinophil extracellular traps and inflammatory pathologies\u2014untangling the web! Front Immunol. 2018;9:2763.","journal-title":"Front Immunol"},{"issue":"Pt B","key":"877_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121191","volume":"311","author":"GA Thompson-Souza","year":"2022","unstructured":"Thompson-Souza GA, Vasconcelos CRI, Neves JS. Eosinophils: focus on DNA extracellular traps. Life Sci. 2022;311(Pt B):121191.","journal-title":"Life Sci"},{"key":"877_CR91","doi-asserted-by":"publisher","first-page":"1448007","DOI":"10.3389\/falgy.2024.1448007","volume":"5","author":"T Weihrauch","year":"2024","unstructured":"Weihrauch T, Melo RCN, Gray N, Voehringer D, Weller PF, Raap U. Eosinophil extracellular vesicles and DNA traps in allergic inflammation. Front Allergy. 2024;5:1448007.","journal-title":"Front Allergy."},{"issue":"3","key":"877_CR92","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/wjo2.138","volume":"10","author":"SY Wu","year":"2024","unstructured":"Wu SY, Cai BY, Wang TY, Cao ZW, Peng H, Liu HH. Eosinophil extracellular traps in respiratory ailment: pathogenic mechanisms and clinical translation. World J Otorhinolaryngol Head Neck Surg. 2024;10(3):213\u201324.","journal-title":"World J Otorhinolaryngol Head Neck Surg."},{"key":"877_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137091","author":"T Fettrelet","year":"2021","unstructured":"Fettrelet T, Gigon L, Karaulov A, Yousefi S, Simon HU. The enigma of eosinophil degranulation. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22137091.","journal-title":"Int J Mol Sci"},{"key":"877_CR94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.crimmu.2022.03.002","volume":"3","author":"C Lombardi","year":"2022","unstructured":"Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42\u201353.","journal-title":"Curr Res Immunol."},{"issue":"2","key":"877_CR95","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0091-6749(96)70161-6","volume":"98","author":"S Horie","year":"1996","unstructured":"Horie S, Gleich GJ, Kita H. Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol. 1996;98(2):371\u201381.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"877_CR96","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaci.2012.01.057","volume":"129","author":"CN Parmentier","year":"2012","unstructured":"Parmentier CN, Fuerst E, McDonald J, Bowen H, Lee TH, Pease JE, et al. Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. J Allergy Clin Immunol. 2012;129(4):1136\u201342.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"877_CR97","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaci.2013.03.048","volume":"132","author":"TA Doherty","year":"2013","unstructured":"Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol. 2013;132(1):205\u201313.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"877_CR98","doi-asserted-by":"publisher","first-page":"288","DOI":"10.4168\/aair.2014.6.4.288","volume":"6","author":"Y Kanaoka","year":"2014","unstructured":"Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res. 2014;6(4):288\u201395.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"877_CR99","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/cea.12292","volume":"44","author":"MW Johansson","year":"2014","unstructured":"Johansson MW. Activation states of blood eosinophils in asthma. Clin Exp Allergy. 2014;44(4):482\u201398.","journal-title":"Clin Exp Allergy"},{"key":"877_CR100","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3389\/fmed.2017.00075","volume":"4","author":"MW Johansson","year":"2017","unstructured":"Johansson MW. Eosinophil activation status in separate compartments and association with asthma. Front Med (Lausanne). 2017;4:75.","journal-title":"Front Med (Lausanne)."},{"issue":"4","key":"877_CR101","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1165\/ajrcmb.25.4.4456","volume":"25","author":"R Temple","year":"2001","unstructured":"Temple R, Allen E, Fordham J, Phipps S, Schneider HC, Lindauer K, et al. Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. Am J Respir Cell Mol Biol. 2001;25(4):425\u201333.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"877_CR102","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1165\/rcmb.2002-0289OC","volume":"29","author":"CK Wong","year":"2003","unstructured":"Wong CK, Ip WK, Lam CW. Interleukin-3, -5, and granulocyte macrophage colony-stimulating factor-induced adhesion molecule expression on eosinophils by p38 mitogen-activated protein kinase and nuclear factor-[kappa] B. Am J Respir Cell Mol Biol. 2003;29(1):133\u201347.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"877_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067560","volume":"8","author":"S Esnault","year":"2013","unstructured":"Esnault S, Kelly EA, Schwantes EA, Liu LY, DeLain LP, Hauer JA, et al. Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge. PLoS ONE. 2013;8(7):e67560.","journal-title":"PLoS ONE"},{"issue":"1","key":"877_CR104","first-page":"301","volume":"18","author":"Y Kawashima","year":"2019","unstructured":"Kawashima Y, Miyata J, Watanabe T, Shioya J, Arita M, Ohara O. Proteogenomic analyses of cellular lysates using a phenol-guanidinium thiocyanate reagent. J Proteome Res. 2019;18(1):301\u20138.","journal-title":"J Proteome Res"},{"key":"877_CR105","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fimmu.2012.00270","volume":"3","author":"Y Isobe","year":"2012","unstructured":"Isobe Y, Kato T, Arita M. Emerging roles of eosinophils and eosinophil-derived lipid mediators in the resolution of inflammation. Front Immunol. 2012;3:270.","journal-title":"Front Immunol"},{"issue":"1","key":"877_CR106","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.alit.2014.08.003","volume":"64","author":"J Miyata","year":"2015","unstructured":"Miyata J, Arita M. Role of omega-3 fatty acids and their metabolites in asthma and allergic diseases. Allergol Int. 2015;64(1):27\u201334.","journal-title":"Allergol Int"},{"issue":"7503","key":"877_CR107","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature13479","volume":"510","author":"CN Serhan","year":"2014","unstructured":"Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92\u2013101.","journal-title":"Nature"},{"key":"877_CR108","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02354-2019","author":"C Zhu","year":"2020","unstructured":"Zhu C, Weng QY, Zhou LR, Cao C, Li F, Wu YF, et al. Homeostatic and early-recruited CD101(-) eosinophils suppress endotoxin-induced acute lung injury. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.02354-2019.","journal-title":"Eur Respir J"},{"key":"877_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687192","volume":"12","author":"J Miyata","year":"2021","unstructured":"Miyata J, Yokokura Y, Moro K, Arai H, Fukunaga K, Arita M. 12\/15-Lipoxygenase regulates IL-33-induced eosinophilic airway inflammation in mice. Front Immunol. 2021;12:687192.","journal-title":"Front Immunol"},{"key":"877_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1565670","volume":"16","author":"E Ito","year":"2025","unstructured":"Ito E, Hayashizaki R, Hosaka T, Yamane T, Miyata J, Isobe Y, et al. Eosinophils and pleural macrophages counter regulate IL-33-elicited airway inflammation via the 12\/15-lipoxygenase pathway. Front Immunol. 2025;16:1565670.","journal-title":"Front Immunol"},{"issue":"16","key":"877_CR111","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1182\/blood-2011-10-384826","volume":"119","author":"TM Laidlaw","year":"2012","unstructured":"Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790\u20138.","journal-title":"Blood"},{"issue":"6","key":"877_CR112","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jaci.2010.09.021","volume":"126","author":"W Duan","year":"2010","unstructured":"Duan W, Mehta AK, Magalhaes JG, Ziegler SF, Dong C, Philpott DJ, et al. Innate signals from Nod2 block respiratory tolerance and program T(H)2-driven allergic inflammation. J Allergy Clin Immunol. 2010;126(6):1284-93.e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"877_CR113","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1365-2567.2011.03492.x","volume":"134","author":"AM Kvarnhammar","year":"2011","unstructured":"Kvarnhammar AM, Petterson T, Cardell LO. NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists. Immunology. 2011;134(3):314\u201325.","journal-title":"Immunology"},{"issue":"1","key":"877_CR114","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2567.2012.03556.x","volume":"136","author":"AM Kvarnhammar","year":"2012","unstructured":"Kvarnhammar AM, Cardell LO. Pattern-recognition receptors in human eosinophils. Immunology. 2012;136(1):11\u201320.","journal-title":"Immunology"},{"issue":"4","key":"877_CR115","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/cmi.2012.77","volume":"10","author":"CK Wong","year":"2013","unstructured":"Wong CK, Hu S, Leung KM, Dong J, He L, Chu YJ, et al. NOD-like receptors mediated activation of eosinophils interacting with bronchial epithelial cells: a link between innate immunity and allergic asthma. Cell Mol Immunol. 2013;10(4):317\u201329.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"877_CR116","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/cmi.2015.77","volume":"13","author":"D Jiao","year":"2016","unstructured":"Jiao D, Wong CK, Qiu HN, Dong J, Cai Z, Chu M, et al. NOD2 and TLR2 ligands trigger the activation of basophils and eosinophils by interacting with dermal fibroblasts in atopic dermatitis-like skin inflammation. Cell Mol Immunol. 2016;13(4):535\u201350.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"877_CR117","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ni.3443","volume":"17","author":"JS Silver","year":"2016","unstructured":"Silver JS, Kearley J, Copenhaver AM, Sanden C, Mori M, Yu L, et al. Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat Immunol. 2016;17(6):626\u201335.","journal-title":"Nat Immunol"},{"issue":"6","key":"877_CR118","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.jaci.2018.04.013","volume":"141","author":"MA Ghebre","year":"2018","unstructured":"Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J Allergy Clin Immunol. 2018;141(6):2027-36.e12.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"877_CR119","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jaci.2006.02.013","volume":"117","author":"A Barczyk","year":"2006","unstructured":"Barczyk A, Pierzcha\u0142a W, Kon OM, Cosio B, Adcock IM, Barnes PJ. Cytokine production by bronchoalveolar lavage T lymphocytes in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2006;117(6):1484\u201392.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"877_CR120","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1164\/rccm.202305-0924OC","volume":"208","author":"AB Villase\u00f1or-Altamirano","year":"2023","unstructured":"Villase\u00f1or-Altamirano AB, Jain D, Jeong Y, Menon JA, Kamiya M, Haider H, et al. Activation of CD8(+) T cells in chronic obstructive pulmonary disease lung. Am J Respir Crit Care Med. 2023;208(11):1177\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"877_CR121","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.4049\/jimmunol.145.9.2950","volume":"145","author":"T Valerius","year":"1990","unstructured":"Valerius T, Repp R, Kalden JR, Platzer E. Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol. 1990;145(9):2950\u20138.","journal-title":"J Immunol"},{"issue":"5","key":"877_CR122","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.4049\/jimmunol.148.5.1471","volume":"148","author":"A Hartnell","year":"1992","unstructured":"Hartnell A, Kay AB, Wardlaw AJ. IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils. J Immunol. 1992;148(5):1471\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"877_CR123","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1046\/j.1365-2249.1997.4511469.x","volume":"110","author":"C Ishihara","year":"1997","unstructured":"Ishihara C, Ochiai K, Kagami M, Takashahi H, Matsuyama G, Yoshida S, et al. Human peripheral eosinophils express functional interferon-gamma receptors (IFN-gammaR). Clin Exp Immunol. 1997;110(3):524\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"877_CR124","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1165\/ajrcmb.18.3.3019","volume":"18","author":"A Druilhe","year":"1998","unstructured":"Druilhe A, Arock M, Le Goff L, Pretolani M. Human eosinophils express bcl-2 family proteins: modulation of Mcl-1 expression by IFN-gamma. Am J Respir Cell Mol Biol. 1998;18(3):315\u201322.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"877_CR125","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.imlet.2008.03.005","volume":"118","author":"T Yamaguchi","year":"2008","unstructured":"Yamaguchi T, Kimura H, Kurabayashi M, Kozawa K, Kato M. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5. Immunol Lett. 2008;118(1):88\u201395.","journal-title":"Immunol Lett"},{"issue":"10","key":"877_CR126","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1164\/rccm.200506-859OC","volume":"173","author":"A Papi","year":"2006","unstructured":"Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114\u201321.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"877_CR127","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.4049\/jimmunol.157.4.1678","volume":"157","author":"W Luttmann","year":"1996","unstructured":"Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC Jr., Kroegel C. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol. 1996;157(4):1678\u201383.","journal-title":"J Immunol"},{"issue":"3","key":"877_CR128","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2169\/internalmedicine.36.179","volume":"36","author":"S Horie","year":"1997","unstructured":"Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S, et al. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern Med. 1997;36(3):179\u201385.","journal-title":"Intern Med"},{"issue":"3","key":"877_CR129","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1165\/ajrcmb.20.3.3326","volume":"20","author":"W Luttmann","year":"1999","unstructured":"Luttmann W, Matthiesen T, Matthys H, Virchow JC Jr. Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-alpha on eosinophil activation in vitro. Am J Respir Cell Mol Biol. 1999;20(3):474\u201380.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11","key":"877_CR130","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"877_CR131","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","volume":"42","author":"AB Molofsky","year":"2015","unstructured":"Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity. 2015;42(6):1005\u201319.","journal-title":"Immunity"},{"issue":"6","key":"877_CR132","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.jaci.2008.04.005","volume":"121","author":"WB Cherry","year":"2008","unstructured":"Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484\u201390.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"877_CR133","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/labinvest.2008.82","volume":"88","author":"M Suzukawa","year":"2008","unstructured":"Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest. 2008;88(11):1245\u201353.","journal-title":"Lab Invest"},{"key":"877_CR134","doi-asserted-by":"publisher","DOI":"10.1111\/all.70313","author":"E Matsuyama","year":"2026","unstructured":"Matsuyama E, Miyata J, Mochimaru T, Onozato R, Otsu Y, Sasaki H, et al. IL-33 drives inflammatory changes and extracellular trap formation in eosinophils involving oxidised LDL and complement pathways. Allergy. 2026. https:\/\/doi.org\/10.1111\/all.70313.","journal-title":"Allergy"},{"issue":"3","key":"877_CR135","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.alit.2024.03.002","volume":"73","author":"M Arima","year":"2024","unstructured":"Arima M, Ito K, Abe T, Oguma T, Asano K, Mukherjee M, et al. Eosinophilic mucus diseases. Allergol Int. 2024;73(3):362\u201374.","journal-title":"Allergol Int"},{"issue":"10056","key":"877_CR136","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128\u201341.","journal-title":"Lancet"},{"issue":"2","key":"877_CR137","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","volume":"69","author":"H Nagase","year":"2020","unstructured":"Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int. 2020;69(2):178\u201386.","journal-title":"Allergol Int"},{"issue":"13","key":"877_CR138","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"25","key":"877_CR139","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358.","journal-title":"N Engl J Med"},{"issue":"24","key":"877_CR140","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024;391(24):2337\u201349.","journal-title":"N Engl J Med"},{"issue":"26","key":"877_CR141","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"877_CR142","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","volume":"378","author":"KF Rabe","year":"2018","unstructured":"Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475\u201385.","journal-title":"N Engl J Med"},{"issue":"19","key":"877_CR143","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139.","journal-title":"N Engl J Med"},{"issue":"18","key":"877_CR144","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","volume":"385","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385(18):1656\u201368.","journal-title":"N Engl J Med"},{"issue":"3","key":"877_CR145","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","volume":"148","author":"SG Kelsen","year":"2021","unstructured":"Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021;148(3):790\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"877_CR146","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","volume":"9","author":"KF Rabe","year":"2021","unstructured":"Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med. 2021;9(11):1288\u201398.","journal-title":"Lancet Respir Med"},{"key":"877_CR147","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00718-2023","author":"KF Rabe","year":"2024","unstructured":"Rabe KF, Martinez FJ, Bhatt SP, Kawayama T, Cosio BG, Mroz RM, et al. AERIFY-1\/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD. ERJ Open Res. 2024. https:\/\/doi.org\/10.1183\/23120541.00718-2023.","journal-title":"ERJ Open Res"},{"issue":"5","key":"877_CR148","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","volume":"10","author":"AJ Yousuf","year":"2022","unstructured":"Yousuf AJ, Mohammed S, Carr L, Yavari Ramsheh M, Micieli C, Mistry V, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med. 2022;10(5):469\u201377.","journal-title":"Lancet Respir Med"},{"issue":"10543","key":"877_CR149","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(26)00637-9","volume":"407","author":"A Papi","year":"2026","unstructured":"Papi A, Greening NJ, Bhatt SP, Roche N, Celli B, Wedzicha JA, et al. Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026;407(10543):2027\u201339.","journal-title":"Lancet"},{"key":"877_CR150","doi-asserted-by":"publisher","DOI":"10.1093\/ajrccm\/aamag226","author":"JA Wedzicha","year":"2026","unstructured":"Wedzicha JA, Agust\u00ed \u00c0, Brightling CE, Calverley P, Chalmers JD, Greening NJ, et al. Astegolimab for copd with frequent exacerbations: pooled analysis of the aliento and arnasa trials. Am J Respir Crit Care Med. 2026;aamag226. https:\/\/doi.org\/10.1093\/ajrccm\/aamag226.","journal-title":"Am J Respir Crit Care Med."},{"key":"877_CR151","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024","author":"D Singh","year":"2025","unstructured":"Singh D, Guller P, Reid F, Doffman S, Sepp\u00e4l\u00e4 U, Psallidas I, et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur Respir J. 2025. https:\/\/doi.org\/10.1183\/13993003.02231-2024.","journal-title":"Eur Respir J"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00877-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:04:05Z","timestamp":1793045045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00877-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":151,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00877-y","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This work was supported by Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Young Scientists (20K17239) (to J.M.), JSPS Grant-in-Aid for Scientific Research (C) (24K11605 to J.M.), the Japan Agency for Medical Research and Development (22ek0410097 and 25ek0410138 to J.M.), RIKEN Special Postdoctoral Researchers Program (to J.M.), GSK Japan Research Grant 2018 (to J.M.), and Grant-in-Aid for Research of the ONO Medical Research Foundation (to J.M.). No specific funding was received for the preparation of this narrative review beyond these existing research grants.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.M. has received lecture fees from Sanofi, AstraZeneca, and GSK. S.C. has received lecture fees from AstraZeneca. K.F. has received lecture fees from Sanofi, AstraZeneca, GSK, Novartis, Boehringer Ingelheim, and Kyorin. The authors declare that they have no other competing interests related to this manuscript.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative review and does not involve any new studies with human participants or animals performed by the authors.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No new datasets were generated or analyzed in the preparation of this review.","order":6,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.M. conceived the topic and overall structure of the review. J.M. drafted the initial manuscript. K.S. and S.C. contributed to the literature review, interpretation of multi-omics data and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}